Development of automated assays for anticardiolipin antibodies determination: Addressing antigen and standardization issues

Annals of the New York Academy of Sciences

Volumn 1109, Issue , 2007, Pages 493-502

  Capuano, Francesco ^a   Grasso, Valentina ^b   Belforte, Luca ^b   Pallavicini, Luca ^a   Tincani, Angela ^c   Andreoli, Laura ^c   Bonelli, Fabrizio ^a  

^a Diasorin SpA   (Italy)

^b CENTRO RICERCHE FIAT   (Italy)

^c SPEDALI CIVILI   (Italy)

Author keywords

Anticardiolipin antibodies; Antiphospholipid syndrome; Immunoassay; LIAISON 2 glycoprotein I purification; SEM

Indexed keywords

ANTIGEN; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ANTIBODY DETECTION; AUTOANALYSIS; BINDING AFFINITY; CHEMOLUMINESCENCE; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; PROTEIN PURIFICATION; SCANNING ELECTRON MICROSCOPY; SENSITIVITY AND SPECIFICITY; SOLID; ARTICLE; BLOOD; IMMUNOLOGY;

ANTIBODIES, ANTICARDIOLIPIN; ANTIGENS; HUMANS; MICROSCOPY, ELECTRON, SCANNING;

EID: 34848906896     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1398.055     Document Type: Conference Paper

References (20)

1. PETERSEN, E., M.V. BOROBIO, E. GUY, et al. 2005. European Multicenter Study of the LIAISON Automated Diagnostic System for Determination of Toxoplasma gondii-Specific Immunoglobulin G (IgG) and IgM and the IgG Avidity Index. J. Clin. Microbiol. 43: 1570-1574.
2. REVELLO, M.G., G. GORINI & G. GERNA. 2004. Clinical evaluation of a chemiluminescence immunoassay for determination of immunoglobulin G avidity to human cytomegalovirus. Clin. Diagn. Lab. Immunol. 11: 801-805.
3. MARANGONI, A., V. SAMBRI, S. ACCARDO, et al. 2005. Evaluation of LIAISON Treponema Screen, a novel recombinant antigen-based chemiluminescence immunoassay for laboratory diagnosis of syphilis. Clin. Diagn. Lab. Immunol. 12: 1231-1234.
4. ERSFELD, D.L., D.S. RAO, J.J. BODY, et al. 2004. Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin. Biochem. 37: 867-874.
5. WURM, H. 1984. Beta-2-glycoprotein-I (apoliprotein H) interactions with phospholipids vesicles. Int. J. Biochem. 16: 511-515.
6. MIYAKIS, S., M.D. LOCKSHIN, T. ATSUMI, et al. 2006. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4: 295-306.
7. MCNEIL, H.P., R.J. SIMPSON, C.N. CHESTERMAN & S.A. KRILIS. 1990. Antiphospholipids antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation of β2-glycoprotein I (apolipoprotein H). Proc. Natl. Acad. Sci. USA 87: 4120.
8. GALLI, M.P., P. CONFURIOUS, C. MAASSEN, et al. 1990. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335: 1544.
9. HUNT, J.E., H.P. MC NEIL, G.J. MORGAN, et al. 1992. A phospholipid β2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with the infection. Lupus 1: 75-81.
10. KOIKE, T. & E. MATSUURA. 1996. Anti β2-glycoprotein I antibody: specificity and clinical significance. Lupus 5: 378-380.
11. SCHWARZENBECHER, R., K. ZETH, K. DIEDERICHS, et al. 1999. Crystal structure of human β2-glycoprotein I: implications for phospholipids binding and the antiphospholipid syndrome. EMBO J. 18: 6228-6239.
12. SANGHERA, D.K., D.R. WAGENKNECHT, J.A. MCINTYRE & M.I. KAMBOH. 1997. Identification of structural mutations in the fifth domain of apolipoprotein H (β2-glycoprotein I) which affect phospholipid binding. Human Mol. Gen. 6: 311-316.
13. MEHDI, H., A. NAQVI & M.I. KAMBOH. 2000. A hydrophobic sequence at position 313-316 (Leu-Ala-Phe-Trp) in the fifth domain of apolipoprotein H (β2-glycoprotein I) is crucial for cardiolipin binding. Eur. J. Biochem. 267: 1770-1778.
14. MATSUURA, E., J. INAGAKI, H. KASAHARA, et al. 2000. Proteolytic cleavage of β2-glycoprotein I: reduction of antigenicity and the structural relationship. Int. Immunol. 12: 1183-1192.
15. KOIKE, T. & E. MATSUURA. 1996. Anti β2-glycoprotein I antibody: specificity and clinical significance. Lupus 5: 378-380.
16. ROUBEY, R.A., R.A. EISENBERG, M.F. HARPER & J.B. WINDFILED. 1995. "Anticardiolipin" autoantibodies recognize β2-glycoprotein I in the absence of phospholipids. Importance of Ag density and bivalent binding. J. Immunol. 154: 954-960.
17. SHENG, Y., D.A. KANDIAH & S.A. KRILIS. 1998. Anti β2-glycoprotein I autoantibodies from patients with the "antiphospholipids" syndrome bind to β2-glycoprotein I with low affinity: dimerization of β2-glycoprotein I induces a significant increase in anti β2-glycoprotein I antibody affinity. J. Immunol. 161: 2038-2043.
18. HARRIS, E.N., A.E. GHARAVI, M.L. BOEY, et al. 1983. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2: 1211-1214.
19. ICHIKAWA, K.A., A. TSUTSUMI, T. ATSUMI, et al. 1999. A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies. Arthritis Rheum. 42: 2461-2470.
20. HARRIS, E.N. & S.S. PIERANGELI. 2002. Revisiting the anticardiolipin test and its standardization. Lupus 11: 269-275.